Ondine Biomedical Inc. (AIM:OBI)

London flag London · Delayed Price · Currency is GBP · Price in GBX
10.25
0.00 (0.00%)
Mar 2, 2026, 4:13 PM GMT
-12.39%
Market Cap 53.25M
Revenue (ttm) 1.18M
Net Income (ttm) -12.79M
Shares Out 519.55M
EPS (ttm) -0.03
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 505,258
Average Volume 129,951
Open 10.50
Previous Close 10.25
Day's Range 10.25 - 10.50
52-Week Range 7.50 - 18.50
Beta 0.24
RSI 88.39
Earnings Date May 12, 2026

About Ondine Biomedical

Ondine Biomedical Inc., a life-sciences company, engages in the development and commercialization of antimicrobial therapies in Canada and internationally. Its primary product is Steriwave, which enables rapid elimination of pathogens associated with healthcare-associated infections. In addition, the company offers a pipeline of products for various indications, including burns, ventilator tube, and sinus; and serious and chronic wounds, chronic sinusitis, ventilator-associated pneumonia VAP, and central line bloodstream infections, as well as ... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1996
Employees 18
Stock Exchange London Stock Exchange AIM
Ticker Symbol OBI
Full Company Profile

Financial Performance

In 2024, Ondine Biomedical's revenue was 2.05 million, an increase of 70.32% compared to the previous year's 1.20 million. Losses were -19.10 million, 32.5% more than in 2023.

Financial numbers in CAD Financial Statements

News

There is no news available yet.